eligibility_summary
Eligibility: Adults 18–75 with histologically/cytologically confirmed PDAC or IPMN-derived cancer, recurrent/unresectable locally advanced, or resectable but ineligible/refusing surgery, ECOG 0–1, ≥3‑mo life expectancy, adequate renal/hepatic/hematologic function, use contraception (to 6 mo post-therapy), consent/compliance. Exclude: pregnant/lactating, anti-tumor therapy <28 days, high-risk EUS anatomy/technical issues, other malignancy <5 yrs (except BCC, cervical CIS), other serious conditions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06478459: Early Phase 1, single-arm, dose-escalation study in unresectable locally advanced pancreatic cancer testing NKG2D CAR-NK cells. Intervention: biological cell therapy (engineered natural killer cells) delivered by endoscopic ultrasound–guided intratumoral injection (day 0) plus two intravenous infusions (days 4–5). Mechanism: NK cells engineered with an NKG2D-based chimeric antigen receptor to recognize stress-induced NKG2D ligands on tumor cells (e.g., MICA, MICB, ULBP family), activating NK cytotoxic pathways (NKG2D signaling, perforin/granzyme release, cytokine production) to kill cancer cells. Targets: tumor cells expressing NKG2D ligands, pathways: NKG2D receptor–ligand axis and innate immune activation within the pancreatic tumor microenvironment. Primary aim: safety with assessment of antitumor activity.